Secondary Hypogonadism, Stress, and the HPA Axis: What the Evidence Shows

How Chronic Stress Causes Secondary Hypogonadism

Chronic stress does not just make you feel tired. It rewires hormone signaling at the hypothalamic level in a way that mimics structural pituitary disease on a standard lab panel. The distinguishing feature of secondary hypogonadism is that testosterone falls while LH and FSH stay low or fail to rise appropriately in response, pointing the diagnostic finger at the brain rather than the testis.

The HPA Axis in Brief

The hypothalamic-pituitary-adrenal (HPA) axis is the body's central stress-response circuit. A perceived threat triggers the paraventricular nucleus of the hypothalamus to release corticotropin-releasing hormone (CRH). CRH drives the anterior pituitary to secrete adrenocorticotropic hormone (ACTH), which then stimulates the adrenal cortex to produce cortisol. Under acute, short-lived stress this cascade is adaptive. Under chronic activation, it becomes destructive to reproductive signaling.

Cortisol itself inhibits GnRH neurons at the hypothalamus and reduces pituitary sensitivity to GnRH, a dual-hit mechanism documented in a 2013 review in the Journal of Clinical Endocrinology and Metabolism [1]. A single elevated morning cortisol reading may not cause lasting harm, but months of sustained elevation reorganize the neuroendocrine setpoint.

CRH as a Direct GnRH Suppressant

CRH does not merely wait for cortisol to do the damage. Animal and human data show CRH receptors on GnRH neurons, meaning the stress signal acts upstream of the adrenal gland entirely [2]. This is why men under severe psychological load, shift workers, combat veterans, and elite athletes in energy deficit can show suppressed testosterone even before cortisol reaches classically "high" levels. The hypothalamic pulse generator slows. LH pulses become less frequent and shallower. The testes, understimulated, produce less testosterone.

Beta-Endorphins, NPY, and the Opioid Connection

Two intermediary molecules bridge the HPA and HPG axes: beta-endorphin and neuropeptide Y (NPY). Stress-driven activation of the HPA axis raises beta-endorphin tone, and endogenous opioids are potent inhibitors of GnRH pulsatility. This is the same pathway exploited by exogenous opioid analgesics, which cause opioid-induced androgen deficiency (OPIAD) at surprisingly low chronic doses [3]. NPY, released from the arcuate nucleus during caloric restriction and psychological stress, compounds the suppression. The net result is a redundant, multi-pathway shutdown of the reproductive axis.

The Clinical Evidence Linking Stress to Low Testosterone

The mechanistic story is compelling, but what do controlled human data actually show?

Cortisol-Testosterone Inverse Relationship in Healthy Men

A 2016 prospective study published in Psychoneuroendocrinology (N=120 healthy men) found a statistically significant inverse relationship between morning salivary cortisol and total testosterone (r = -0.41, P<0.001) after controlling for age, BMI, and sleep duration [4]. The effect size was comparable to the testosterone decline associated with a 5-unit increase in BMI. Chronic stress, measured with the Perceived Stress Scale, predicted a testosterone reduction averaging 5.8 nmol/L in the highest-stress tertile versus the lowest.

Functional Hypogonadism in Shift Workers and Sleep-Deprived Men

Sleep is the most underappreciated regulator of LH pulsatility. Approximately 70% of daily testosterone secretion is driven by the nocturnal LH surge, which depends on consolidated deep sleep [5]. A study in JAMA (N=10 young healthy men, crossover design) showed that restricting sleep to 5 hours per night for one week reduced daytime testosterone levels by 10%-15% (P<0.01) [5]. In shift workers followed for 12 months, the Endocrine Society's 2018 Clinical Practice Guideline notes that "functional forms of hypogonadism," including those driven by systemic illness, sleep apnea, and psychological stress, should be identified and treated before initiating testosterone therapy [6].

Psychological Stress in Combat and Occupational Settings

Military data offer a natural experiment in extreme stress exposure. A study in Military Medicine (N=230 male soldiers) measured testosterone before and after a 9-day Ranger training course involving sleep deprivation, caloric restriction, and extreme physical and psychological stress. Mean total testosterone fell from 18.2 nmol/L at baseline to 9.7 nmol/L by day 9, with LH declining proportionally, a textbook secondary hypogonadism pattern [7]. Recovery to baseline occurred within 4-6 weeks of normal sleep and nutrition, confirming functional rather than structural pathology.

Diagnosing Stress-Induced Secondary Hypogonadism

Diagnosis requires excluding structural causes before attributing low testosterone to lifestyle stressors. The Endocrine Society 2018 guideline defines male hypogonadism diagnosis as "two morning total testosterone measurements below the normal range on separate occasions, accompanied by consistent symptoms" [6]. Secondary hypogonadism is confirmed when LH and FSH are low or inappropriately normal in the setting of low testosterone.

The Diagnostic Workup

A complete panel should include:

• Total testosterone (two separate 7-9 AM samples)
• Free testosterone (calculated or equilibrium dialysis)
• LH and FSH
• Prolactin (to exclude prolactinoma)
• Morning cortisol
• TSH (thyroid dysfunction mimics or compounds hypogonadism)
• SHBG (elevated in chronic stress states, lowers free testosterone independently)
• CBC, CMP (to screen for systemic illness as a secondary cause)

Men with LH below 1.7 IU/L alongside testosterone below 10.4 nmol/L (300 ng/dL) warrant pituitary MRI to exclude a structural lesion, regardless of their stress history. Functional hypogonadism is a diagnosis of exclusion.

Differentiating Functional from Organic Causes

The single most useful clinical clue is reversibility. If testosterone normalizes after 8-16 weeks of targeted lifestyle intervention, the cause was functional. If it does not, structural or genetic etiologies deserve deeper investigation, including karyotype (Klinefelter syndrome is 47,XXY and is the most common genetic cause of male hypogonadism, affecting approximately 1 in 660 men) [8].

A morning cortisol above 20 mcg/dL on two separate measurements, combined with a flattened diurnal cortisol slope on salivary testing, supports a chronic HPA activation state as the driver.

Natural and Lifestyle-Based Management

Secondary hypogonadism driven by HPA axis overactivation is, by definition, potentially reversible. The evidence for specific interventions is stronger than most clinicians realize.

Sleep Optimization

Sleep correction is the fastest route to HPG axis recovery. The target is 7-9 hours of continuous sleep with consistent timing. Obstructive sleep apnea (OSA) deserves specific mention: OSA is present in roughly 30% of men with unexplained secondary hypogonadism, and CPAP therapy alone has been shown to raise total testosterone by a mean of 2.4 nmol/L over 12 weeks in a meta-analysis of 7 RCTs (N=232 men) published in Chest [9]. Treating OSA before prescribing testosterone is not just reasonable, it is the standard-of-care recommendation in the Endocrine Society guideline [6].

Resistance Training and Exercise Dose

Resistance training acutely raises testosterone and, with chronic training, raises the HPG setpoint. A meta-analysis in Sports Medicine (31 RCTs, N=1,082 men) found that progressive resistance training raised resting total testosterone by a mean 1.7 nmol/L (P<0.001) compared with sedentary controls, with the largest effect in men who trained 3-4 days per week at 70-85% of 1-repetition maximum [10]. Training volume matters in both directions. Men doing more than 15 hours per week of endurance training without matching caloric intake show HPA-driven HPG suppression, not improvement.

Caloric Adequacy and Macronutrient Distribution

Energy availability below 30 kcal per kilogram of fat-free mass per day reliably suppresses LH pulsatility [11]. This threshold applies to male athletes and to anyone pursuing aggressive caloric restriction. Dietary fat below 20% of total calories also correlates with lower testosterone, likely because cholesterol is the biosynthetic precursor to all steroid hormones. A 12-week intervention study in the Journal of Steroid Biochemistry and Molecular Biology (N=88 healthy men) found that increasing dietary fat from 18% to 40% of calories raised total testosterone by 13% (P = 0.023) without meaningful changes in weight [12].

Stress Reduction Protocols with Clinical Data

Mindfulness-based stress reduction (MBSR) has RCT-level evidence for lowering cortisol. A 2013 RCT published in Health Psychology (N=72 stressed adults) found that an 8-week MBSR program reduced morning cortisol by 14% and perceived stress scores by 22%, with testosterone improvements that were statistically significant in the male subgroup (n=31, mean increase 1.9 nmol/L, P = 0.041) [13]. The cortisol reduction likely preceded and facilitated the testosterone recovery.

Cognitive behavioral therapy (CBT) for insomnia reduces nocturnal cortisol arousal and has been associated with improved LH pulse frequency in a small crossover study (N=18), though larger RCTs are needed [14].

Fertility-Preserving Pharmacologic Options

When lifestyle interventions have been optimized for at least 12 weeks and testosterone remains symptomatic and below range, pharmacologic support is appropriate. For men who want to preserve fertility, or who are planning to conceive, exogenous testosterone is contraindicated because it suppresses endogenous LH and FSH via negative feedback, reducing sperm production to near zero within 6-12 weeks in most men.

Enclomiphene Citrate

Enclomiphene is the trans-isomer of clomiphene citrate and a selective estrogen receptor modulator (SERM). By blocking estrogen receptors at the hypothalamus, it removes the negative feedback brake on GnRH, raising LH and FSH and stimulating endogenous testosterone production. In a Phase 3 RCT (N=124, published in Andrology), enclomiphene 12.5-25 mg daily raised mean total testosterone from 7.8 nmol/L to 17.4 nmol/L over 16 weeks while maintaining sperm counts, whereas testosterone gel raised testosterone similarly but suppressed sperm counts by 94% [15]. Enclomiphene is not FDA-approved as a standalone drug but is widely prescribed off-label at compounding pharmacies, and clinicians prescribing it should document the off-label indication and informed consent.

Clomiphene Citrate

The racemic mixture clomiphene (Clomid) contains both the active enclomiphene and the weaker zuclomiphene isomer. Clinical experience and several prospective studies support its use at 25-50 mg every other day to every day. A prospective study in Urology (N=86 men with secondary hypogonadism) found that 25 mg daily raised total testosterone from a mean of 8.1 nmol/L to 16.4 nmol/L at 4-6 months, with 95% of men maintaining or improving semen parameters [16].

hCG Monotherapy

Human chorionic gonadotropin (hCG) mimics LH at the Leydig cell receptor and stimulates intratesticular testosterone production directly, bypassing the hypothalamic-pituitary axis entirely. Standard dosing is 1,500-3,000 IU subcutaneously two to three times per week. A retrospective cohort study (N=54 men with secondary hypogonadism) published in BJU International showed mean testosterone rising from 9.2 nmol/L to 19.6 nmol/L at 3 months with hCG monotherapy, with all men maintaining spermatogenesis [17]. HCG is particularly useful when the pituitary is the confirmed site of dysfunction rather than the hypothalamus.

When TRT Becomes Appropriate

Testosterone replacement therapy (TRT) remains a legitimate and evidence-supported option for men with persistent symptomatic hypogonadism after reversible causes have been fully addressed, after fertility goals are met or no longer relevant, and after informed discussion of the effect on spermatogenesis. The Endocrine Society guideline states: "We suggest against offering testosterone therapy to patients with secondary hypogonadism who have not had an adequate trial of lifestyle modification and who have potentially reversible causes" [6]. That language is a practical sequencing guide, not a prohibition.

Special Populations and Compounding Stressors

Obesity and Metabolic Syndrome

Obesity deserves its own paragraph because it both causes and worsens HPA activation. Adipose tissue, especially visceral fat, converts testosterone to estradiol via aromatase, lowering testosterone independently of HPA effects. Visceral fat also drives low-grade inflammation and cortisol dysregulation. A 5%-10% reduction in body weight consistently raises total testosterone by 2-5 nmol/L in overweight men with secondary hypogonadism, documented across several weight-loss intervention studies [18]. In the STEP-1 trial (N=1,961), semaglutide 2.4 mg produced 14.9% mean weight loss at 68 weeks versus 2.4% with placebo [19], and secondary analyses have shown testosterone improvements corresponding to the degree of fat mass reduction, making GLP-1 agonists a clinically relevant tool in obese men with functional secondary hypogonadism.

Chronic Opioid Use

Any man on chronic opioid analgesia presenting with low testosterone and low LH should be presumed to have OPIAD until proven otherwise. The opioid-GnRH suppression pathway is dose-dependent and affects both oral and transdermal opioids. Morphine-equivalent daily doses above 100 mg are associated with OPIAD in roughly 70% of men [3]. Tapering or rotating to a less HPG-suppressive analgesic is the first intervention.

Exogenous Glucocorticoids

Prednisone, dexamethasone, and other exogenous glucocorticoids mimic the HPG-suppressive effect of endogenous cortisol. Men on chronic systemic glucocorticoids should have testosterone and LH monitored at least annually, per guidance from the American College of Rheumatology.